{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:43:39Z","timestamp":1793033019576,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["xjh012019063"],"award-info":[{"award-number":["xjh012019063"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002412","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.eclinm.2022.101425","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T06:16:26Z","timestamp":1651731386000},"page":"101425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases"],"prefix":"10.1016","volume":"48","author":[{"given":"Jingjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsuo","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl","key":"10.1016\/j.eclinm.2022.101425_bib0001","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2022.101425_bib0002","unstructured":"World Health Organization. Hepatitis B. Accessed at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b on December 11, 2021."},{"issue":"8","key":"10.1016\/j.eclinm.2022.101425_bib0003","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-019-0177-z","article-title":"Too many people with viral hepatitis are diagnosed late - with dire consequences","volume":"16","author":"Lazarus","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5 Suppl","key":"10.1016\/j.eclinm.2022.101425_bib0004","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101425_bib0005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101425_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101425_bib0007","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.immuni.2006.03.001","article-title":"CTLA4Ig: bridging the basic immunology with clinical application","volume":"24","author":"Bluestone","year":"2006","journal-title":"Immunity"},{"issue":"6370","key":"10.1016\/j.eclinm.2022.101425_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101425_bib0009","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation","volume":"183","author":"Walunas","year":"1996","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101425_bib0010","first-page":"703","article-title":"CTLA\u20114 interferes with the HBV\u2011specific T cell immune response","volume":"42","author":"Cao","year":"2018","journal-title":"Int J Mol Med"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101425_bib0011","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2011.10.011","article-title":"Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept","volume":"56","author":"Germanidis","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101425_bib0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/rheumatology\/ket221","article-title":"Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection","volume":"53","author":"Fanouriakis","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.eclinm.2022.101425_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40360-016-0060-2","article-title":"Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report","volume":"17","author":"Talotta","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.eclinm.2022.101425_bib0014","unstructured":"U.S. Food and Drug Administration. The FDA adverse event reporting system (FAERS) public dashboard. Accessed at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard on September 20, 2021."},{"issue":"10","key":"10.1016\/j.eclinm.2022.101425_bib0015","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/0895-4356(92)90158-J","article-title":"Serum sickness-like reactions to cefaclor","volume":"45","author":"Stricker","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101425_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.eclinm.2022.101425_bib0017","unstructured":"European Medicines Agency. Eudravigilance, European database of suspected adverse drug reaction reports. Accessed at: https:\/\/www.adrreports.eu\/en\/index.html on December 11, 2021."},{"issue":"10062","key":"10.1016\/j.eclinm.2022.101425_bib0018","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"Stevens","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.eclinm.2022.101425_bib0019","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2022.101425_bib0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.eclinm.2022.101425_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107612","article-title":"A review on applications of abatacept in systemic rheumatic diseases","volume":"96","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101425_bib0022","article-title":"Abatacept for rheumatoid arthritis","volume":"2009","author":"Maxwell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101425_bib0023","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101425_bib0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101425_bib0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101425_bib0026","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101425_bib0027","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","article-title":"Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease","volume":"80","author":"Chen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101425_bib0028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"issue":"21","key":"10.1016\/j.eclinm.2022.101425_bib0029","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","article-title":"Hepatitis B virus reactivation with a rituximab-containing regimen","volume":"7","author":"Tsutsumi","year":"2015","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101425_bib0030","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.0913498107","article-title":"Immune effectors required for hepatitis B virus clearance","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eclinm.2022.101425_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","article-title":"Host-virus interactions in hepatitis B virus infection","volume":"36","author":"Guidotti","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101425_bib0032","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","article-title":"Immunosurveillance of the liver by intravascular effector CD8(+) T cells","volume":"161","author":"Guidotti","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101425_bib0033","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101425_bib0034","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101425_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101425_bib0036","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101425_bib0037","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101425_bib0038","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl C","key":"10.1016\/j.eclinm.2022.101425_bib0039","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin Ther"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022001559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022001559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:12:58Z","timestamp":1762888378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022001559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"alternative-id":["S2589537022001559"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101425","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101425"}}